Evidence map›Paper›PMID 39875664›Full record

Observational studyJournal of the International AIDS Society2025

Benefits of HIV-1 transmission cluster surveillance: a French retrospective observational study of the molecular and epidemiological co-evolution of recent circulating recombinant forms 94 and 132.

Marc Wirden, Fabienne Tombette, Sidonie Lambert-Niclot, Marie-Laure Chaix, Stéphanie Marque-Juillet, Magali Bouvier-Alias, Benedicte Roquebert, Moise Machado, Veronique Avettand-Fenoel, Pierre Gantner and 8 more

Abstract readObservational Study
In one paragraph

Observational study in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Marc WirdenSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de virologie, Paris, France.ORCID https://orcid.org/0009-0003-3723-4142
Fabienne TombetteUniv Rouen Normandie, UNICAEN, INSERM, DYNAMICURE UMR 1311, CHU de Rouen, Service de virologie, Centre National de référence VIH, Rouen, France.
Sidonie Lambert-NiclotAP-HP, Hôpital Saint-Antoine, Service de Virologie, Paris, France.
Marie-Laure ChaixAP-HP, Hôpital Saint-Louis, Service de Virologie, INSERM U944, Paris, France.
Stéphanie Marque-JuilletHôpital de Versailles, Service de Virologie, Le Chesnay, France.
Magali Bouvier-AliasHU Henri Mondor, Service de Virologie, Créteil, France.
Benedicte RoquebertLaboratoire CERBA, Saint Ouen L'Aumône, France.
Moise MachadoGrand Hôpital de l'Est Francilien, Site Marne-La-Vallée, Service des Maladies Infectieuses et Tropicales, Jossigny, France.
Veronique Avettand-FenoelAP-HP, Hôpital Necker, Service de Virologie, Paris, France.
Pierre GantnerHU de Strasbourg, Service de Virologie, Strasbourg, France.
Enagnon Kazali AlidjinouCHU de Lille, Service de Virologie, Lille, France.
Karl SteficCHU de Tours, Service de Virologie, Tours, France.
Jean-Christophe PlantierUniv Rouen Normandie, UNICAEN, INSERM, DYNAMICURE UMR 1311, CHU de Rouen, Service de virologie, Centre National de référence VIH, Rouen, France.
Vincent CalvezSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de virologie, Paris, France.
Diane DescampsAP-HP, Hôpital Bichat Claude Bernard, Service de Virologie, INSERM, IAME, Paris, France.
Anne-Genevieve MarcelinSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de virologie, Paris, France.
Benoit VisseauxAP-HP, Hôpital Bichat Claude Bernard, Service de Virologie, INSERM, IAME, Paris, France.
ANRS‐MIE resistance study group

Funding

This work was supported by ANRS-MIE (Agence Nationale de Recherche sur le SIDA et les Hépatites Virales- Maladies Infectieuses Emergentes).
6 · The paper itself

Abstract

introductionMolecular surveillance is an important tool for detecting chains of transmission and controlling the HIV epidemic. This can also improve our knowledge of molecular and epidemiological factors for the optimization of prevention. Our objective was to illustrate this by studying the molecular and epidemiological evolution of the cluster including the new circulating recombinant form (CRF) 94_cpx of HIV-1, detected in 2017 and targeted by preventive actions in 2018.

methodsIn June 2022, 32 HIV-1 sequence databases from French laboratories were screened to identify all individuals who had acquired CRF94_cpx or a similar strain, whatever the date of diagnosis. Phylogenetic analyses were performed with the sequences identified, and biological parameters were collected at the time of diagnosis and after the start of treatment to analyse the evolution of the cluster. Full genomes were sequenced to characterize the new strains.

resultsWe analysed 98 HIV-1 isolates: 63 were CRF94, three were unclassifiable, and the other 32 formed a new cluster containing a new recombinant, CRF132_94B, derived from CRF94 and a subtype B strain. At least 95% of the individuals in both the CRF94 and CRF132 clusters were men who have sex with men (MSM), most of whom had acquired HIV less than 12 months before diagnosis. The number of CRF94 diagnoses declined drastically after 2018, but CRF132 strains spread widely between 2020 and 2022, into a different area of Ile-de-France region and within a younger population nevertheless aware of pre-exposure prophylaxis. Higher viraemia, lower CD4 cell counts and delayed treatment efficacy suggested that CRF94 was more virulent than CRF132, possibly due to the F subtype fragment of the vif gene.

conclusionsThese findings highlight the role of the MSM transmission cluster in spreading HIV and new variants. They show also the benefits of cluster surveillance for improving the targeting of preventive interventions, detecting the emergence of new strains and enriching our knowledge on virulence mechanisms. However, these investigations require support with sufficient resources dedicated to a regional or national programme to be responsive and effective.

Indexed as

Epidemiological MonitoringEvolution, MolecularHIV-1HIV InfectionsRecombination, GeneticAdultFemaleFranceGenotypeHomosexuality, MaleHumansMaleMiddle AgedMolecular EpidemiologyPhylogenyRetrospective Studiescluster of transmissionCRF132CRF94HIV‐1HIV preventionmolecular surveillance

Identifiers

PMID39875664
PMCPMC11774651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.